1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GSK plc
  6. Summary
    GSK   GB00BN7SWP63

GSK PLC

(GSK)
  Report
Delayed London Stock Exchange  -  11:35 2022-08-12 am EDT
1450.00 GBX   +3.57%
11:13aEuropean ADRs Move Slightly Lower in Friday Trading
MT
11:01aDrugmakers' shares up after Zantac lawsuit slump
RE
10:59aPUMP / DUMP #41 : This week's gainers and losers
MS
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
08/08/2022 08/09/2022 08/10/2022 08/11/2022 08/12/2022 Date
1659.4(c) 1646.8(c) 1556.43184(c) 1400(c) 1450(c) Last
3 254 908 5 624 487 12 919 214 26 874 285 13 535 626 Volume
-0.46% -0.76% -5.49% -10.05% +3.57% Change
More quotes
Estimated financial data (e)
Sales 2022 29 644 M 35 938 M 35 938 M
Net income 2022 4 481 M 5 433 M 5 433 M
Net Debt 2022 15 496 M 18 786 M 18 786 M
P/E ratio 2022 13,4x
Yield 2022 4,14%
Sales 2023 30 544 M 37 028 M 37 028 M
Net income 2023 5 148 M 6 241 M 6 241 M
Net Debt 2023 11 988 M 14 533 M 14 533 M
P/E ratio 2023 11,6x
Yield 2023 3,95%
Capitalization 58 701 M 71 163 M 71 163 M
EV / Sales 2022 2,50x
EV / Sales 2023 2,31x
Nbr of Employees 90 096
Free-Float 93,6%
More Financials
Company
GSK plc, formerly GlaxoSmithKline PLC is a global healthcare company. The Company is focused to improve the quality of human life by helping people. The Company operates through three core businesses: Pharmaceuticals, Vaccines and Consumer Healthcare. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency viruses (HIV), immuno-inflammation and oncology. It also... 
More about the company
Ratings of GSK plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about GSK PLC
11:13aEuropean ADRs Move Slightly Lower in Friday Trading
MT
11:01aDrugmakers' shares up after Zantac lawsuit slump
RE
10:59aPUMP / DUMP #41 : This week's gainers and losers
MS
10:00aBiotech stocks pin bounce back hopes on M&A boost
RE
08:53aFDA and EMA have concluded there is no evidence of a causal association between ranitid..
AQ
06:25aSTATEMENT : Zantac (ranitidine) litigation - Form 6-K
PU
06:06aMARKETSCREENER'S WORLD PRESS REVIEW : August 12, 2022
MS
05:42aEUROPEAN MIDDAY BRIEFING : Shares Edge Higher as Inflation Fears Ease
DJ
05:11aNORTH AMERICAN MORNING BRIEFING : Stock Futures Rise as Debate Over Inflation's Path Conti..
DJ
04:58aFTSE 100 rises after better-than-feared GDP reading
MS
04:47aEuropean shares rise as healthcare, leisure stocks gain
RE
04:24aGSK, Sanofi and Haleon shares stabilise after Zantac litigation slump
RE
03:30aLONDON STOCK EXCHANGE : FTSE 100 climbs on smaller-than-expected GDP contraction, GSK rebo..
RE
03:28aEuropean shares eke out gains at open as healthcare stocks rebound
RE
03:06aShares in gsk rise 4.4%, haleon up 0.5% after heavy sell-off ove…
RE
More news
News in other languages on GSK PLC
05:02pLes Bourses mondiales confortées par la confiance des ménages américains
12:45pLas acciones europeas suben gracias a las ganancias de los valores del sector sanitario..
12:13pAKTIEN EUROPA SCHLUSS : Moderate Gewinne am Ende einer guten Börsenwoche
12:04pPoint marchés-Les actions continuent de profiter du ralentissement de l'inflation
11:13aLes ADR européens évoluent en légère baisse dans la négociation de vendredi
More news
Analyst Recommendations on GSK PLC
More recommendations
Chart GSK PLC
Duration : Period :
GSK plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GSK PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 1 450,00 GBX
Average target price 2 038,46 GBX
Spread / Average Target 40,6%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Jon Ellis VP & Head-Technology Business Development
Tony Wood Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GSK PLC-14.82%69 216
JOHNSON & JOHNSON-2.30%439 441
ELI LILLY AND COMPANY9.03%286 164
ROCHE HOLDING AG-18.19%272 759
PFIZER, INC.-18.22%271 020
ABBVIE INC.4.93%251 211